AbbVie terminates deal with I-Mab to develop cancer drug

NovaBridge Biosciences

22/09/2023 21:28

Sept 22 (Reuters) - China-based biotech company I-Mab
 IMAB.O  said on Friday that AbbVie  ABBV.N  has terminated a
2020 deal to co-develop and market I-Mab's lead cancer drug
candidate lemzoparlimab.

 (Reporting by Mariam Sunny in Bengaluru; Editing by Shounak
Dasgupta)
 ((Mariam.ESunny@thomsonreuters.com))